Sharing of sales structures and management resources through the reorganization of reportable segments
First written in FY2022-Q2. 3 of 6 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Our group has 2 reportable segments based on the nature of its business: “Antibody-Related Business” and “Cosmetics-Related Business.”」
The 2-reportable-segment structure reorganised in the previous fiscal year has continued, with the recombinant silkworm and testing services operated and disclosed within the Antibody-Related Business. - FY2024-Q2RestatedAnnual report
「Our group had previously been classified into 3 reportable segments, “Antibody-Related Business,” “Recombinant Silkworm Development Business” and “Cosmetics-Related Business,” but has changed the classification to 2 reportable segments, “Antibody-Related Business” and “Cosmetics-Related Business,” from the first-quarter consolidated accounting period.」
The 2-reportable-segment structure adopted from the first quarter has continued in the second quarter. The profit or loss of the Recombinant Silkworm Development Business is disclosed within the Antibody-Related Business. - FY2024-Q1ReframedAnnual report
「Our group had previously been classified into 3 reportable segments, “Antibody-Related Business,” “Recombinant Silkworm Development Business” and “Cosmetics-Related Business,” but will change the classification to 2 reportable segments, “Antibody-Related Business” and “Cosmetics-Related Business,” from the first-quarter consolidated accounting period.」
The reportable segments changed from 3 to 2, with the profit or loss of the Recombinant Silkworm Development Business reorganised into the Antibody-Related Business. - FY2023-Q1RestatedAnnual report
「Since the second-quarter consolidated accounting period of the previous fiscal year, we have changed the classification of business segments from “Diagnostics and Reagents Business,” “Recombinant Silkworm Business,” “Testing Business” and “Cosmetics-Related Business” to 3 reportable segments: “Antibody-Related Business,” “Recombinant Silkworm Development Business” and “Cosmetics-Related Business.”」
The 3-segment reportable classification adopted from the second quarter of the previous fiscal year has continued, with first-quarter results disclosed under the Antibody-Related, Recombinant Silkworm Development and Cosmetics-Related segments. - FY2022-Q3AdvancedAnnual report
「Our group had previously been classified into 4 reportable segments, “Diagnostics and Reagents Business,” “Recombinant Silkworm Business,” “Testing Business” and “Cosmetics-Related Business,” but will change the classification to 3 reportable segments, “Antibody-Related Business,” “Recombinant Silkworm Development Business” and “Cosmetics-Related Business,” from the second-quarter consolidated accounting period.」
The reportable segments changed from 4 to 3 based on the similarities and relationships among business partners. The new classification has been used since the second quarter, establishing a framework for sharing sales structures and management resources. - FY2022-Q2First statedAnnual report
「Going forward, in view of the similarities and relationships among our business partners, we will change the classification to 3 reportable segments, “Antibody-Related Business,” “Recombinant Silkworm Development Business” and “Cosmetics-Related Business,” to share sales structures and management resources, accelerate and improve the efficiency of business operations and research and development, and enhance the value of the business group.」
The business groups acquired through the establishment of new companies and M&A were to be reorganised into 3 segments based on the similarities and relationships among business partners, rather than the previous acquisition units, with the sharing of sales structures and management resources and the acceleration and improved efficiency of business operations and research and development specified for the first time.